Malignant melanoma commonly contains high prevalence of genetic mutation and leads to recalcitrant to systemic chemotherapy. During previous 5 years, an eminent advances in drug research and development that targeted on its bio-molecular mechanisms focusing to cancer tumourigenesis and their cellular proliferative phenotype, with promisingly showed a good tumour response for example treatments of gastrointestinal stromal tumor (GIST), non-small cell lung cancer and hepatocellular carcinoma. Therefore, there were plenty of clinical studies to show the benefit of these medications for treating advanced malignant melanoma. The findings of these studies demonstrated withremarkably better improvement in term of clinical outcomes and tumour response than previous conventional chemotherapy. These advances will importantly sufficient for primary physician and health care personnel to explicitly learn and know about how to better treat this group of patients.
